1 ICI 118,551, 5 to 80 mg orally, did not significantly alter resting heart rate or blood pressure. In doses less than 40 mg the reduction in exercise tachycardia was under 10 beats/ min.
Introduction
The widespread use of ,-adrenoceptor antagonists has focused attention on the relative importance of drugs which are selective at 1l-adrenoceptors in clinical practice (Kendall, 1981; McDevitt, 1983) . In contrast 132-selective adrenoceptor antagonists have lacked either selectivity or potency (O'Donnell & Wanstall, 1980) and have received little attention. ICI 118,551 (erythro-(-+-)-1-(7-methylindan-4-yloxy)-3-isopropylamino-butan-2-ol) is a new drug which has been shown to be highly selective at P2-adrenoceptors in animals (O'Donnell & Wanstall, 1980; Cheah et al., 1982; Bilski et al., 1983) . In man, doses of 20 and 50 mg cause significant displacement of the bronchial airway dose-response curve to salbutamol, confirming 620 J. M. 0. Arnold et al. tent to which ICI 118,551 selectively antagonises P2-adrenoceptors in man. The effects of ICI 118,551 have been compared with atenolol and propranolol: in addition, the influence of vagal reflexes on the response to isoprenaline after ICI 118,551 has been assessed.
Methods
Approval for the studies was obtained from the University Ethics Committee. All subjects were non-smoking males who gave written informed consent and showed no abnormality on routine medical examination, twelve lead electrocardiogram and standard laboratory tests.
Study I
Six subjects (aged 23.2 ± 0.98 years; weighing 66.5 ± 2.8 kg; mean ± s.e. mean) completed a randomised double-blind study of the effects of ICI 118,551 on heart rate and blood pressure at rest and during exercise. At weekly intervals, following a light breakfast containing no caffeine, the subjects received either ICI 118, 551, 5, 10, 20, 40, 80 mg (ICI 5, 10, 20, 40, 80 mg) or placebo as identical oral syrup preparations. Two hours later, heart rate and blood pressure were measured at the end of 15 min supine rest and 3 min erect position. Heart rate was measured from limb lead II of an electrocardiogram, as the shortest time between six consecutive R waves. Blood pressure was measured using a semiautomated sphygmomanometer (Critikon Exercise Monitor, Model 1165). Each subject then completed 3 min of a standard exercise step test (46 cm step, 32 steps/min); blood pressure was measured during the last 45 s, and heart rate within 5 s of completion of exercise. (Arnold & McDevitt, 1984a) . Tremor was measured as the summated integrator ramp heights over the third minute of recording.
On each study day, after 30 min supine rest, an 8 min intravenous infusion of saline 0.9% was followed by four graded sequential 8 min infusions of isoprenaline sulphate, freshly prepared with sodium metabisulphite 0.1% as preservative. For each drug treatment, every subject received the same four isoprenaline infusion rates, the largest of which was chosen so that heart rate did not increase by more than 50 beats/min, and systolic pressure did not rise more than 50 mm Hg or exceed an absolute pressure of 160 mm Hg. During each 8 min infusion, measurements of individual parameters were taken as follows: heart rate between 3.0-3.5 min; blood pressure between 3.5-5.0 min; forearm blood flow and finger tremor between 5-8 min. Changes are expressed with reference to the control values obtained during saline infusion. Finger tremor is calculated as percentage change from control (Arnold & McDevitt, 1984a) .
Venous blood samples were taken before the saline infusion and immediately after the last isoprenaline infusion. Aliquots (10 ml) were placed on ice immediately and assayed colorimetrically for free fatty acids (Duncombe, 1964) . Samples (3 ml) were centrifuged, the serum stored at -40°C and serum insulin subsequently assayed by radioimmunoassay using a double antibody separation system, with an international reference preparation 66/304 as standard (Hales & Randle, 1963) . Serum potassium and plasma glucose were measured routinely in the hospital laboratory. Thirty minutes after the end of the isoprenaline infusion an exercise test was performed with measurement of heart rate and blood pressure as described for Study 1.
Subsequently, under identical conditions separated by 1 week, each subject received propranolol 10 mg and atenolol 25 mg orally, singleblind, in a randomised order, and the same measurements were made with isoprenaline and exercise. On one further occasion, after a light lunch, each subject received ICI 118,551 20 mg (ICI 20 mg) orally. Ninety minutes later, intravenous isoprenaline infusions were given and measurements of heart rate, blood pressure, forearm blood flow and finger tremor were made as before. Thirty minutes after the last isoprenaline infusion, atropine sulphate 0.04 mg/kg was administered by slow intravenous injection and, when heart rate had restabilised, the whole procedure was repeated.
The results were compared statistically by analysis of variance. Contrasts between groups were assessed by Duncan's multiple range technique (Duncan, 1955) for the isoprenaline induced changes in finger tremor and haemodynamic variables, and by the t method for the other variables. A log transformation of the data was used in the analysis of the isoprenalineenhanced changes in tremor and forearm blood flow. As some values were negative the value 50 was added to the tremor measurements and the value 0.4 to the blood flow measurements before the loge transformation was perfonned. Student's paired t-test was also used to compare paired data. Results are expressed as the arithmetic or geometric mean where appropriate.
Results
The subjects did not complain of side-effects due to ICI 118,551 and none was observed during the study.
Study I
After placebo, heart rate and diastolic blood pressure were significantly greater in the standing than in the supine position but systolic pressure was not altered: exercise significantly increased systolic blood pressure and heart rate. There were no significant differences in systolic or diastolic pressure in the supine or standing positions, and during the last 45 s of exercise following treatment with any doses of ICI 118,551 in comparison to placebo (Table 1) . Standing systolic pressure following ICI 80 mg (100.0 mm Hg) was significantly lower than after ICI 10 mg (108.5 mm Hg; P < 0.05) and ICI 5 mg (112.0 mm Hg; P < 0.01). Supine heart rate was significantly decreased after ICI 5, 40 and 80 mg compared with placebo. Supine heart rate after ICI 40 mg was significantly decreased compared to ICI 5, 10 and 20 mg. No significant changes were observed on standing heart rate between drug treatments and placebo, or between drug treatments. Exercise heart rate was significantly reduced compared with placebo by ICI 40 and 80 mg. Lower doses of ICI 118,551 had no significant effects. Exercise heart rates after ICI 5 and 20 mg were significantly greater than after ICI 80 mg.
Study 2
Although performed within the same six subjects, the studies with atenolol and propranolol were conducted after the randomised administration of ICI 118,551. Thus, a possible order Table 2 for isoprenaline infusion rates of 2 and 4 ,ug/min, as these two doses were the only ones given with placebo and all active treatments.
Heart rate ( Figure 1 and Table 2 ) Compared to placebo, each of the active treatments shifted the dose-response curve to the right. Atenolol appeared to be least effective, the three doses of ICI 118,551 showed increasing dose-related effects with ICI 40 mg similar to propranolol.
Blood pressure (Figures 2 and 3 and Table 2 ) The fall in diastolic pressure was attenuated by ICI 10 mg, but more so by ICI 20 and 40 mg, which were comparable to propranolol (Figure 2 ). Atenolol shifted the dose-response curve to the right. The rise in systolic pressure did not appear to be prevented by ICI 10, 20 or 40 mg but was significantly reduced by propranolol at 4 ,ug/min (Figure 3 ). Mean pressure was reduced with placebo and atenolol but increased by propranolol and all doses of ICI 118,551.
Forearm bloodflow ( Figure 4 and Table 2 ) All three doses of ICI 118,551 reduced the isoprenaline-induced increases in forearm blood flow. Although atenolol also attenuated the response, the effect was less marked than with ICI 118,551, which was comparable to propranolol.
Finger tremor ( Figure 5 and (n = 6).
Atenolol had no significant effects on any of these metabolic changes.
Effects of active treatments on exercise heart rate and blood pressure With placebo, exercise heart rate was 170.0 ± 7.0 beats/min. Small reductions occurred with ICI 10 mg (163.2 ± 6.9 beats/min; P < 0.05), ICI 20 mg (162.0 ± 6.6 beats/min; P < 0.05) and ICI 40 mg (158.5 ± 5.0 beats/min; P < 0.001). Propranolol and atenolol produced larger reductions in exercise tachycardia (147.7 ± 6.1 and 133.3 ± 5.8 beats/min respectively; P < 0.001). Systolic (159.8 ± 2.1 mm Hg) and diastolic pressure (64.7 ± 11.3 mm Hg) with placebo were not altered by any active drug.
Effects of atropine on the changes produced by isoprenaline in the presence ofICI 118,551 20 mg Following ICI 20 mg the changes were similar to those seen previously in the same subjects. The increase in heart rate was decreased, the fall in diastolic pressure was less and the increase in systolic pressure was unaffected ( Figure 6 and Table 4 ). At 4 ,ug/min, although mean pressure was increased compared to placebo (+5.7 ± 3.2 and -8.4 ± 4.2 mm Hg respectively; P < 0.01), the rise in pulse pressure was less (32.3 ± 4.0 and 52.8 ± 3.8 mm Hg respectively; P < 0.001). Atropine enhanced the heart rate increases, although the changes remained significantly less than with placebo. The fall in diastolic pressure tended to be enhanced as the dose of isoprenaline increased, so at 6 ,ug/min, the fall was 8. (0) propranolol. Atenolol, the PI-selective adrenoceptor antagonist, had a smaller but nevertheless significant effect on both of these parameters even at a dose of 25 mg; such an effect on diastolic pressure has been reported previously (Conway et al., 1976) . Forearm blood flow has been used previously in the assessment of Padrenoceptor antagonists, with either intraarterial isoprenaline (Brick et al., 1968; Briant et al., 1973) , or intravenous bolus injections (Mougeot et al., 1981; . During intravenous administration, changes in forearm blood flow may be influenced by proximal cardiovascular changes, for example, in perfusion pressure. In the present study, mean blood pressure showed a small increase with ICI 118,551. This would tend to increase blood flow, and hence the observed reductions by ICI 118,551 in the increases in forearm blood flow produced by isoprenaline may have been underestimated. Enhancement of physiological finger tremor by isoprenaline infusions has been shown to provide a means for distinguishing between the effects of selective and non-selective ,-adrenoceptor antagonists (Arnold & McDevitt, 1984a 18.3 ± 3.4 2.6 ± 2.1** 1.7 ± 0.5 0.4 ± 0.2** 354 ± 129 16 ± 11** 1.7 ± 1.9** 4.2 ± 1.6** 9.3 ± 1.9** 12.5 ± 2.0* 0.3 ± 2.2** +1.8 ± 2.1** 2.2 ± 1.7** 8.3 ± 1.2** 4.7 ± 1.8** 5.2 ± 1.3** 1.5 ± 1.7** 5.8 ± 2.4** 0.5 ± 0.2** 0.5 ± 0.1** 0.3 ± 0.2** 0.9 ± 0.2 2 ± 3** 23 ± 10** 1 ± 13** 131 ± 31* 0.5 ± 2.2** 3.3 ± 3.4** 15.0 ± 3.9** 0.9 ± 0.3** 0.8 ± 0.4** 1.5 ± 0.5** 16±8** 18±11** 277±69 *P < 0.05, **P < 0.01 compared with placebo
In the present study, all doses of ICI 118,551 markedly reduced the isoprenaline-induced increases in tremor. This is consistent with the finding that it competitively inhibits the isoprenaline-induced decrease in twitch tension in the cat soleus muscle (Smith et al., 1983) , an action which would predict a decreased tremor in human muscles (Marsden et al., 1967; Marsden & Meadows, 1968) . The effects of ICI 118,551 on finger tremor were similar to propranolol but different from atenolol which, nonetheless, resulted in some attenuation of tremor responses. The metabolic tests used were chosen because they are influenced by stimulation of 12-adrenoceptors (Leitch et al., 1976; Holgate et al., 1980) . Isoprenaline induced significant changes in each metabolic parameter, though the effect on free fatty acid was not sensitive to the degree of antagonism studied, a finding which has been observed previously (Harms et al., 1978 .
The hypokalaemia which occurs with adrenaline infusions is also antagonised by low doses of ICI 118,551 (2.5 and 5 mg) (Brown etal., 1983) , and by the non-selective antagonist, timolol, but not by atenolol (Struthers et al., 1981 Isoprenaline sulphate (,ug/min) Figure 6 Isoprenaline-induced changes in heart rate with placebo (-), ICI 118,551 20 mg (A) and ICI 118,551 20 mg + atropine (*). Points are shown as mean ± s.e. mean (n = 6).
Of particular interest was the observed reduction in isoprenaline-induced increases in heart rate by all doses of ICI 118,551 given. Similar changes have been described by Fitzgerald et al. (1982) . The dose-response curves obtained were comparable to those with atenolol and propranolol (see Figure 1) ; the lower doses of ICI 118,551 appeared to be more effective than atenolol and the 40 mg dose similar to propranolol 10 mg. Exercise tachycardia was unaffected by low doses of ICI 118,551 and therefore it is unlileely that this reduction was due to 01-adrenoceptor antagonism. Since part of the drug's action is to prevent a fall in diastolic pressure and increase in forearm blood flow produced by isoprenaline, it is possible that the effect on heart rate might be influenced by indirect changes in cardiovascular reflexes, notably vagal tone. This was tested by comparing the effects of ICI 118,551 20 mg before and after atropine. The results indicate that atropine enhanced the heart rate response to isoprenaline in the presence of ICI 118,551, implying that vagal tone is increased rather than decreased. This is compatible with the observed increases in mean blood pressure, even though the rise in pulse pressure was reduced. The increase in mean pressure would be expected to stimulate baroreceptors. It is also consistent with previous reports that cardiac vagal tone is increased during continuous isoprenaline infusions (Arnold & McDevitt, 1984b) .
Even after atropine, ICI 118,551 significantly reduced the isoprenaline tachycardia as com-,pared to placebo (see Figure 6 ). In fact, this difference is greater than it appears, since the placebo curve would also be shifted to the left by atropine (Arnold & McDevitt, 1984b) . Thus ICI 118,551 appears to have a direct effect on the isoprenaline-induced changes in heart rate. In view of the other results from this study, it would appear that the 02-adrenoceptors in the heart are functionally active (Ablad etal., 1974; Brodde et al., 1983 with cardioselective drugs (Dunlop & Shanks, 1968; McDevitt, 1977) , but though the presence of such a reflex has been confirmed, it does not account for all of the observed differences between these two, types of drugs .
